Recent studies on cannabinoid-induced analgesia implicate certain transient receptor potential (TRP) channels as a therapeutic target along with metabotropic cannabinoid receptors. Although TRP ankyrin 1 (TRPA1)-selective cannabinoids, such as (R)- WIN55,212), are effective at desensitizing TRPA1 and TRP vanilloid 1 (TRPV1), there is a gap in knowledge in understanding the opposite situation, namely whether TRPV1-selective cannabinoids desensitize TRPA1. We selected the TRPV1-specific synthetic cannabinoid, arachidonoyl-2 chloroethanolamine (ACEA), to study peripheral antihyperalgesic properties because ACEA is known to activate TRPV1. Hence, we used in vitro as well as in vivo assays to evaluate the following: 1) the effects of ACEA on the TRPA1-selective agonist, mustard oil (MO), for calcitonin generelated peptide (CGRP) release from rat hindpaw skin in vitro; 2) the effects of a peripherally selective dose of ACEA on MOinduced nocifensive behavior in vivo; and 3) the effects of five ACEA-insensitive TRPV1 mutations on ACEA-inhibition of MOevoked calcium accumulation using a Chinese hamster ovary cell expression system. Our results demonstrate that 1) ACEA significantly attenuated (ϳ40%) MO-evoked CGRP release from rat hindpaw skin, and this effect was not antagonized by the TRPV1 antagonist, capsazepine; 2) ACEA significantly inhibited (ϳ40%) MO-induced nocifensive behavior in wild-type mice but not in TRPV1 knockout mice; and 3) all TRPV1 mutations insensitive to ACEA lacked the ability to inhibit MO-evoked calcium accumulation in Chinese hamster ovary cells transfected with TRPV1 and TRPA1. Taken together, the results indicate that a TRPV1-selective cannabinoid, ACEA, inhibits MO-evoked responses via a TRPV1-dependent mechanism. This study strengthens the hypothesis that cannabinoids mediate their peripheral analgesic properties, at least in part, via the TRP channels.
Introduction
The desensitization of transient receptor potential vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1) activities is a logical target for development of analgesics because gene deletion studies have shown that mice with genetic deletion of either TRPV1 (Caterina et al., 2000; Davis et al., 2000; Szabó et al., 2005) or TRPA1 (Bautista et al., 2006; Kwan et al., 2006) display significantly reduced nociceptive behaviors in several preclinical pain models. In addition, both TRPV1 and TRPA1 are present on 20 to 40% of sensory neurons, including a substantial proportion that responds to noxious stimuli (Caterina et al., 2000; Bautista et al., 2005) . Thus, both TRPV1 and TRPA1 are important integrators of peripheral noxious stimuli.
Numerous studies have demonstrated that both synthetic and plant-derived cannabinoids produce robust antinociception in preclinical pain models. However, their precise mechanism(s) of action remains unclear. The traditional hypothesis is that cannabinoids mediate antihyperalgesia and antinociception via activation of the G protein-coupled cannabinoid receptors, CB1 and CB2. For example, many studies have reported that (R)-(ϩ)- [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo-[1,2,3-d,e]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone (WIN55,212) evokes antinociception and antihyperalgesia via the G protein-coupled CB1 receptor using pharmacological blockade or gene deletion studies (Zimmer et al., 1999; Johanek et al., 2001; Johanek and Simone, 2004; Agarwal et al., 2007) . In addition, the antihyperalgesic properties of (2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl]-methanone (AM1241) and cannabilactones have been attributed exclusively to the CB2 receptor (Malan et al., 2001 Ibrahim et al., 2003 Ibrahim et al., , 2005 Quartilho et al., 2003; Gutierrez et al., 2007; Khanolkar et al., 2007) . However, recent studies have demonstrated an alternative mechanism by which cannabinoids modulate nociceptive transmission via ionotropic receptors. Agonist-induced desensitization of the TRPA1 channel can result in the peripheral antinociceptive effect of certain cannabinoids, such as WIN55,212 . Additional studies have demonstrated that cannabinoid inhibition of TRPA1 activities leads to a heterologous desensitization of TRPV1 Akopian et al., 2007 Akopian et al., , 2009 Ruparel et al., 2008) , similar to the cross-desensitization observed with prototypical TRPA1 and TRPV1 agonists such as mustard oil (MO) and capsaicin (Akopian et al., 2007; Ruparel et al., 2008) . In addition, six different phytocannabinoids, such as cannabidiol, tetrahydrocannabinol, cannabichromene, and cannabigerol, have been shown to activate TRPA1 but antagonize responses of TRP melastatin 8 in vitro; moreover, cannabidiol serves as a cannabinoid agonist of TRPV2 (De Petrocellis et al., 2008; Qin et al., 2008; Di Marzo and De Petrocellis, 2010) .
Although TRPA1-selective cannabinoids such as WIN55,212 and AM1241 are effective at desensitizing TRPV1 via a calciumdependent calcineurin pathway , there is a gap in knowledge in understanding whether the reverse is true, namely whether TRPV1-selective cannabinoids lead to the heterologous desensitization of TRPA1. Accordingly, we have evaluated whether arachidonyl-2 chloroethanolamine (ACEA), a TRPV1-selective cannabinoid, triggers heterologous desensitization of TRPA1.
Materials and Methods
Animals. All animal study protocols were approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio and conformed to the International Association for the Study of Pain and U.S. government guidelines. Animals were housed for 1 week before the experiment, and food and water were available ad libitum. Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), weighing 250 to 300 g, were used for the skin superfusion assays for release of calcitonin gene-related peptide (CGRP), and C57BL/6J wild-type (WT) and C57BL/6J TRPV1(Ϫ/Ϫ) mice were used for the behavioral experiments.
Neuropeptide Release Assay. The release of immunoreactive CGRP (iCGRP) from isolated hindpaw skin biopsies was performed as described previously (Kilo et al., 1997; Ruparel et al., 2008) , except that the skin biopsies (6-7-mm diameter) dissected from glabrous rat hindpaws were simply immersed into 2-ml wells containing various treatment conditions in a modified Hanks' buffer (containing 10.9 mM HEPES, 4.2 mM sodium bicarbonate, 10 mM dextrose, and 0.1% bovine serum albumin, pH adjusted to 7.4 at 303 mOsmol/kg). The TRPA1-selective agonist MO (Sigma-Aldrich, St. Louis, MO) Akopian et al., 2007) , ACEA and capsazepine (CPZ; both from Tocris Bioscience, Ellisville, MO) were diluted with Hanks' buffer for the assays.
For the desensitization experiments, two biopsies per well were placed into 24-well plates containing 1.2 ml of Hanks' buffer (37°C) and, after a wash period and collection of two 20-min baseline samples, were exposed to either vehicle or 100 M CPZ for 20 min. The biopsies were then treated for 20 min with either vehicle, 100 M ACEA, 100 M CPZ, or the combination of 100 M CPZ and 100 M ACEA. The skin was then exposed to a 10-min vehicle-washout period, which was followed by a 2-min application of 0.1% MO . The total evoked iCGRP release was measured by pooling the 2-min exposure sample with the subsequent 18-min vehicle-exposure sample. Biopsies were used only once.
iCGRP Radioimmunoassay. The CGRP radioimmunoassay was conducted essentially as described previously (Kilo et al., 1997; Patwardhan et al., 2006; Ruparel et al., 2008) . In brief, 100 l of primary antibody against CGRP (final dilution, 1:10 6 ; kindly donated by Dr. M. J. Iadarola, National Institutes of Health, Bethesda, MD) was added to 1-ml aliquots and incubated at 4°C for 48 h. After this incubation, 100 l of [
125 I]-Tyr 0 -CGRP 28-37 (ϳ2 ϫ 10 4 cpm) and 50 l of goat anti-rabbit antisera coupled to ferric beads (Applied Biosystems, Foster City, CA) were added to the tubes and incubated at 4°C for an additional 24 h. The reaction was stopped using immunomagnetic separation of bound from the free tracer. The minimal detectable levels for CGRP for this assay were ϳ3 fmol/ml and the 50% displacement was ϳ30 fmol. All test compounds were evaluated for potential interference in the radioimmunoassay.
Behavioral Assays. On the day of the experiment, MO was diluted in mineral oil and ACEA [stock made in 100% methyl-2-pyrrolidinone solution) (MPL); Sigma-Aldrich] was diluted to 27% MPL/saline. Preliminary studies demonstrated no differences between mineral oil and MPL/saline vehicle-treated animals, and therefore the final vehicle control consisted of MPL/saline. All animals were acclimatized in empty cages for 20 to 30 min, and all studies were conducted by observers blinded to treatment allocation.
WT and TRPV1(Ϫ/Ϫ) mice were given a 15-l intraplantar injection of either vehicle or ACEA (100 g) followed by a 10-l intraplantar injection of 0.1% MO 15 min later. The duration (in seconds) spent grooming and flinching the injected hindpaw over a 5-min period for MO-induced behavior was measured. For experiments evaluating the peripheral action of ACEA, 15 l of either vehicle or ACEA (100 g) was injected into the contralateral hindpaw, whereas 15 l of vehicle and then (after 15 min) 10 l of MO (0.1%) was injected into the ipsilateral paw.
Constructs and Heterologous Expression in Chinese Hamster Ovary Cells. Expression plasmids of TRPV1 (GenBank accession no. NM031982) in pcDNA3 (Invitrogen, Carlsbad, CA) and of TRPA1 (GenBank accession no. NM177781) in pcDNA5/FRT (Invitrogen) were used. The TRPV1 mutants Y511A and S512Y in pcDNA3 were kindly provided by Dr. David Julius (University of California, San Francisco, San Francisco, CA). All other TRPV1 mutations were custom made in pcDNA3 (TOP Gene, Montreal, QC, Canada). Expression constructs with a visual marker (green fluorescent protein expressing pEGFP-N1; Clontech, Mountain View, CA) were delivered into Chinese hamster ovary (CHO) cells using PolyFect (QIAGEN, Valencia, CA) according to the manufacturers' protocols. CHO cells were subjected to experimental procedures within 24 to 48 h after transfection. Ca 2؉ Imaging in CHO Cells. The Ca 2ϩ imaging experiments were performed as described previously (Diogenes et al., 2006; Akopian et al., 2007) . All drugs and compounds were dissolved in modified 1ϫ Hanks' buffer containing 10.9 mM HEPES, 4.2 mM sodium bicarbonate, 10 mM dextrose, and 1.8 mM calcium chloride (pH adjusted to 7.4) as described previously . Only green fluorescent protein-positive cells were selected for experiments. The net changes in Ca 2ϩ accumulation were calculated by subtracting the basal [Ca 2ϩ ] i (mean value collected for 60 s before agonist application) from the peak [Ca 2ϩ ] i value achieved after ex-posure to the agonists. Data are presented as an absorption ratio of 340/380. A ratio greater than 0.02 was considered positive because this value represents the mean ϩ2 S.D. of basal values observed from Ͼ300 untreated cells. For experiments evaluating the effects of ACEA on TRPV1 mutants, CHO cells transfected with either WT TRPV1 alone or any of the mutations were first washed in Hanks' buffer followed by collection of baseline values for 60 s. The cells were then treated with either vehicle (Hanks' buffer) or 100 M ACEA for 2 min and washed again with buffer.
For the desensitization experiments, CHO cells were doubly transfected with TRPA1 and either WT TRPV1 or a selected TRPV1 mutant. Cells were washed for 60 s to collect baseline values, after which they were treated with either vehicle or 100 M ACEA for 2 min. The cells were then washed for 4 min and then treated with a 25-M MO for 2 min. Finally, the cells were washed again for approximately 2 to 3 min.
Electrophysiology. Recordings were made in perforated patch voltage-clamp configuration [holding potential (V h ) of Ϫ60 mV] at 22-24°C from CHO cells. Data were acquired and analyzed using an Axopatch 200B amplifier and pCLAMP 9.0 software (Molecular Devices, Sunnyvale, CA). Recording data were filtered at 0.5 kHz and sampled at 2 kHz. Borosilicate pipettes (Sutter, Novato, CA) were polished to resistances of 7 to 10 M⍀ in the perforated patch pipette solution. Access resistance (R s ) was compensated (40-80%) when appropriate up to the value of 15 to 20 M⍀. Data were rejected when leak currents were Ͼ50 pA or input resistance was Ͻ300 M⍀. Currents were considered positive when their amplitudes were 5-fold larger than displayed noise (in root mean square). Standard external solution contained the following: 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM D-glucose, and 10 mM HEPES, pH 7.4. The standard pipette solution for the perforated patch whole-cell configurations contained the following: 140 mM KCl, 1 mM MgCl 2 , 10 mM D-glucose, 10 mM HEPES, pH 7.3, and 250 g/ml amphotericin B.
Data Analysis. All iCGRP release desensitization experiments were conducted with n ϭ 4 to 6 wells/group and repeated at least three times for statistical analysis. Overall, a sample size (n) of 12 to 18 was used for statistical analysis for these experiments. The data are presented as percentage above basal levels of iCGRP (mean Ϯ S.E.M.), and the measured basal CGRP levels (i.e., in femtomoles per mole) are provided in the figure legends. The behavioral experiments were performed with n ϭ 6 to 8 mice/group, and the data are presented as time (seconds) spent displaying nocifensive behavior (mean Ϯ S.E.M.). All calcium-imaging experiments were performed three times, and a sample size of 50 to 100 cells after pooling data was used for statistical analysis. For experiments comparing only two groups, an unpaired Student's t test was performed; all other experiments were analyzed by two-way analysis of variance with Dunnett's multiple comparison test. Data were analyzed using Prism software version 4.0 (GraphPad Software Inc., San Diego, CA).
Results
ACEA Cross-Desensitizes TRPA1 In Vitro. We have shown previously that the TRPA1/CB1/CB2 cannabinoid agonist WIN55,212 heterologously inhibits capsaicin-induced responses in vitro as well as in vivo via activation of TRPA1 Akopian et al., 2008) . In the present study, we tested the opposite hypothesis, namely that a TRPV1-selective cannabinoid could heterologously desensitize a TRPA1-mediated effect. To conduct these studies, we used the synthetic cannabinoid, ACEA, which is a TRPV1-selective cannabinoid and has no effect on TRPA1 (Price et al., 2004; Akopian et al., 2009) , and tested for inhibition of MO, a TRPA1-selective agonist Akopian et al., 2009 Taken together, these data are consistent with the hypothesis that ACEA desensitizes peripheral terminals of MO-responsive peptidergic fibers.
ACEA Cross-Desensitizes TRPA1 In Vivo. We next examined the physiological significance of this finding by performing in vivo nocifensive behavioral experiments. The assay was based on previously published reports (Caterina et al., 2000; Bautista et al., 2006; Kwan et al., 2006) . In brief, mouse hindpaws were first given intraplantar injections of ACEA (no distinct nocifensive behavior was observed compared to the vehicle group) followed by an injection of 0.1% MO 15 min later. The amount of time spent by the animal in displaying nocifensive behavior over the first 5 min after MO was recorded. A 100-g dose of ACEA significantly inhibited MO-induced nocifensive behavior in WT mice ( Fig. 2A) . In control experiments, the injection of ACEA alone did not induce a significant nocifensive response (Veh ϭ 0.2 Ϯ 0.2 s versus ACEA ϭ 3.6 Ϯ 2.2 s; p is nonsignificant). To confirm that the effects of ACEA were mediated via TRPV1, we repeated the study in TRPV1(Ϫ/Ϫ) mice and observed that ACEA inhibition of MO was abolished in these animals ( Fig. 2A) .
To evaluate the site of ACEA action (i.e., central versus peripheral), we injected 100 g of ACEA into the contralateral paw and MO into the ipsilateral paw. Our results indicate that a 100-g ACEA dose injected contralaterally did not inhibit MO-induced nocifensive behavior (Fig. 2B) . This result clearly demonstrates that the inhibitory effect of ACEA Fig. 1 . ACEA inhibits MO-evoked CGRP release. Skin biopsies were collected from male rat hindpaws, exposed to pretreatment with either Veh or CPZ (100 M), followed by either Veh or ACEA (100 M); all groups were then exposed to mustard oil (0.1%) for 2 min, which was combined with a subsequent 18-min exposure to a modified Hanks' buffer. iCGRP was measured by radioimmunoassay, and mean basal levels (ϭ 100%) were 5 to 6 fmol/ml. n ϭ 12 to 18; error bars ϭ S.E.M.; ‫,ء‬ p Ͻ 0.05.
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at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org is peripheral and is mediated at the local site of injection. It is noteworthy that the response of MO-induced nocifensive behavior was lower in TRPV1 knockout mice compared with the WT mice ( Fig. 2A) . This finding could be attributed to the absence of TRPV1 in null-mutant animals that leads to attenuation in TRPA1-mediated responses in sensory neurons (Akopian et al., 2007; Salas et al., 2009) . Taken together, our data, for the first time, demonstrate that a TRPV1-selective cannabinoid agonist heterologously cross-desensitizes TRPA1 responses in vitro as well as in vivo.
ACEA-Insensitive TRPV1 Mutants Do Not Desensitize TRPA1. We next used calcium imaging of CHO expression systems to confirm and extend these findings. To confirm the involvement of TRPV1, we first compared WT TRPV1 responses to five different TRPV1 mutants (Fig. 3) . Because ACEA has structural similarities to anandamide and capsaicin (Zygmunt et al., 1999; Jordt and Julius, 2002) , we selected several capsaicin-insensitive TRPV1 mutants (Jordt and Julius, 2002; Jung et al., 2002; Gavva et al., 2004) as likely channels that would be also insensitive to ACEA. Our data confirmed that these selected TRPV1 mutations were indeed insensitive to capsaicin (Fig. 3A) as well as insensitive to ACEA (Fig. 3B) . To confirm the selectivity of ACEA, we used whole-cell voltage-clamp to measure ACEAactivated current in CHO cells transfected with either TRPV1 (Fig. 3C) or TRPA1 (Fig. 3D) . It is noteworthy that the application of ACEA induced an inward current in TRPV1-positive but not TRPA1-positive cells.
Next, we studied the effect of these ACEA-insensitive TRPV1 mutants on the inhibition of MO-evoked calcium accumulation in the CHO expression system. Our initial experiments coexpressed equimolar amounts of WT TRPA1 DNA with either WT TRPV1 DNA or a selected TRPV1 mutant DNA (Fig. 4, A and B) . However, because quantification was not done, the "equimolar" ratio is an assumption based on the amount of cDNA given to cells. It is noteworthy that the cotransfection of an equimolar amount of TRPA1 partially "rescued" the TRPV1 mutants such that they now demonstrated responsiveness to ACEA (Fig. 4A versus Fig.  3B ) as well as ACEA-evoked inhibition of MO-evoked calcium accumulation (Fig. 4B) . In general, the coexpression of TRPA1 with the TRPV1 mutants produced two patterns of responses to ACEA (Fig. 4A) , some mutants (i.e., S511Y, 761Glu, and T550I) demonstrating increased responsiveness relative to WT TRPV1 and other mutants (i.e., Y512A and 114Arg) only partially rescuing ACEA responses. These effects can be attributed to the copresence of TRPA1 in CHO cells (Fig. 4A versus Fig. 3B ).
Several TRP channels are known to physically interact, leading to key conformational changes in the final protein assembly (Xu et al., 2000; Hofmann et al., 2002; Hellwig et al., 2005) . It is possible that transfection of equimolar amounts of TRPA1 DNA and TRPV1 DNA permits a physical interaction between TRPV1 and TRPA1 that leads to conformational changes in the TRPV1 mutants (Salas et al., 2009; Staruschenko et al., 2010) , thereby restoring their sensitivity to ACEA. To test this hypothesis, we designed a coexpression experiment in which the dose of WT TRPA1 DNA was five times greater than WT TRPV1 DNA, or with various TRPV1 mutant DNAs (i.e., a TRPV1/TRPA1 DNA dose ratio of 5:1). Under these transfection conditions, all five mutations showed significantly reduced sensitivity to ACEA (Fig. 4, C  versus A) . Accordingly, in the same experimental set, all five mutations that were ACEA-insensitive then failed to desensitize MO-evoked calcium accumulation, with the exception of TRPV1 mutation T550I (Fig. 4, B versus D) .
Taken together, these results confirm our CGRP data that ACEA heterologously desensitizes MO responses in vitro and that this effect requires activation of TRPV1 by ACEA. In addition, our data suggest that an interaction between TRPV1 and TRPA1 modifies the biophysical properties of the heteromer, leading to alteration of TRPV1 mutant responsiveness to agonists, namely capsaicin and ACEA.
Discussion
The peripheral antinociceptive and antihyperalgesic effects of cannabinoids have been well documented and recognized (Richardson et al., 1998) , but the mechanism(s) mediating this effect is still not elucidated in detail. Nevertheless, there is an agreement that mechanisms of cannabinoid peripheral effects could be dependent on types of cannabinoids, types of involved cannabinoid receptors, direct inhibition of sensory neurons, and modulations of non-neuronal peripheral cells that will eventually result in inhibition of sensory neurons. We have demonstrated that WIN55,212, a combined CB1/CB2 agonist, inhibits TRPV1 responses via activation of the TRPA1 channel on sensory neurons Patwardhan et al., 2006; Akopian et al., 2008 ).
The current study tested the hypothesis that a CB1-activating cannabinoid, ACEA , triggers the heterologous desensitization of TRPA1 via a TRPV1 pathway. Our results indicate that 1) ACEA significantly attenuates MO-evoked CGRP release from rat hindpaw; 2) ACEA significantly inhibits MO-induced short-term nociception in WT mice, and this effect is abolished in TRPV1 knockout mice; and 3) ACEA is capable of inhibiting MO-induced calcium accumulation in vitro, but only under conditions in which TRPV1 is functionally responsive to ACEA. Taken together, these data demonstrate that ACEA inhibits TRPA1 responses via a TRPV1-dependent mechanism. The TRPV1 mutant experiments were designed to test whether ACEA inhibition of MO-evoked calcium accumulation required the coexpression of cannabinoid-responsive TRPV1 protein. The results provided strong support for this possibility because ACEA was able to suppress MO effects only under conditions in which either the WT or mutant TRPV1 was responsive to ACEA (the only exception was T550I).
It is noteworthy that the application of an equimolar (1:1) amount of TRPA1 DNA with TRPV1 mutant DNA partially rescued the ACEA responsiveness not observed in homomeric TRPV1 mutant channels (Figs. 4A versus 3B ). Considering that ACEA is not able to activate TRPA1 (Fig. 4D) , one plausible explanation for this effect is that TRPA1 interaction with TRPV1 could create conformational changes in the TRPV1 channel, which will lead to its new pharmacological properties (Salas et al., 2009; Staruschenko et al., 2010) . Thus, it was shown previously that AM1241 is more potent in TRPA1-TRPV1 expressing sensory neurons than in cells expressing TRPA1 alone .
To begin to address this possibility, we designed an overexpression experiment using the TRPV1 mutants with TRPA1 (5:1 dose ratio), reasoning that this might increase the probability of forming ACEA-insensitive homomeric channels consisting of TRPV1 mutants. As predicted, the results demonstrate reduced ACEA responsiveness under these conditions. Overall, these studies provide additional evidence that complex formation between TRPV1 and TRPA1 could lead to different pharmacological properties of individual channels. This result could have important implications during pathological pain states when each channel is activated by endogenous ligands.
Cannabinoids can exert their effects via either metabotropic or ionotropic receptors. These mechanisms are complex because some cannabinoid agonists can act on both GPCR receptors and channels. This multiplicity of mechanisms may be somewhat restricted, considering that cannabinoids act on channels in sensory neurons and GPCR receptors on mainly peripheral nonneuronal cells . Thus, ACEA is likely to mediate its peripheral analgesic effects via the TRPV1 and CB1 receptors, targeting TRPV1 on sensory neurons and CB1 on non-neuronal peripheral cells. However, there are data that point toward expression of CB1 expression in sensory neurons. In such circumstances, cross-talk between GPCRs and ionotropic cannabinoid receptors could be considered. Indeed, recent reports suggest that TRPV1 responses may be sensitized by the CB1 agonist, HU-210, and that constitutive CB1 activity maintains TRPV1 in a sensitized state (Hermann et al., 2003; Fioravanti et al., 2008) . Thus, cross-talk among CB1 and TRP channels may occur when colocalized on the cellular domain. However, although we did not perform studies with CB1-null mice or CB1 antagonists, the data obtained here in CHO cells, in which CB1 receptors are not expressed, allow us to suggest that no such CB1-TRPV1 cross-talk is involved in the effect of ACEA on MO-induced activation of TRPA1.
In conclusion, this study supports and strengthens the hypothesis that the peripheral effects of cannabinoids are mediated, at least in part, by ionotropic TRP channels. Although the findings do not exclude a potential role for metabotropic cannabinoid receptors in peripheral cannabinoid analgesia, they do reveal that cannabinoids can desensitize TRPV1 and TRPA1 via homologous and heterologous mechanisms. Furthermore, the results provide further support to a growing body of evidence of the possible formation of TRPV1/TRPA1 heteromeric channels.
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